1613 completed. 1613 Phase 2, 387 Phase 1, 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1613 | Completed 1613 |
| Phase 1 | 387 | Completed 387 |
| Phase 3 | 16 | Completed 16 |
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) [6,6-²H₂]-Glucose - Glioma, GBM | Phase 2 | Completed | Stanford University | 2 | 2025-01-30 | 2026-09-30 |
| A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma B10 L-BPA Injection - Meningioma, Boron Neutron Capture Therapy | Phase 1 / Phase 2 | Completed | Heron Neutron Medical Corp. | 10 | 2024-10-14 | 2026-05-11 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors IMM-6-415 - Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | Phase 1 / Phase 2 | Completed | Immuneering Corporation | 30 | 2024-02-27 | 2025-05-28 |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| A Study of GC101 TIL in Advanced Melanoma (BZ) GC101 TIL - Tumor Infiltrating Lymphocytes, Safety | Phase 1 / Phase 2 | Completed | Shanghai Juncell Therapeutics | 18 | 2023-11-08 | 2025-12-23 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors nab-sirolimus - Neuroendocrine Tumors, NET | Phase 2 | Completed | Aadi Bioscience, Inc. | 12 | 2023-10-20 | 2026-08-25 |
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma TN-TC11G, Temozolomide Oral Product, Radiotherapy - Glioblastoma | Phase 1 / Phase 2 | Completed | Grupo Español de Investigación en Neurooncología | 33 | 2023-08-18 | 2026-02-12 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| Sonodynamic Therapy With ExAblate System in Glioblastoma Patients 5-Aminolevulinic Acid - Glioblastoma Multiforme | Phase 2 | Completed | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 5 | 2023-02-22 | 2024-11-12 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
| Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Tislelizumab, Sitravatinib - Uveal Melanoma With Liver Metastases | Phase 2 | Completed | Grupo Español Multidisciplinar de Melanoma | 16 | 2022-09-23 | 2026-06-01 |
| A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma RO7247669 - Melanoma | Phase 2 | Completed | Hoffmann-La Roche | 93 | 2022-08-15 | 2026-02-04 |
| Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Pembrolizumab 25 MG/1 ML Intravenous Solution - Metastatic Uveal Melanoma | Phase 2 | Completed | Institut Curie | 51 | 2022-07-07 | 2026-07-28 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 20 | 2022-05-24 | 2026-03-05 |
Showing 20 of 1613. Sign in to see all of them.
Melanoma (602) · Glioblastoma (428) · Brain Neoplasms (261) · Glioma (229) · Gliosarcoma (189) · Central Nervous System Neoplasms (174) · Astrocytoma (159) · Neuroblastoma (121) · Oligodendroglioma (106) · Sarcoma (98) · Neuroendocrine Tumors (95) · Neoplasms (94) · Neoplasm Metastasis (76) · Uveal Melanoma (63) · Medulloblastoma (57)
Neoplasms by Histologic Type (1610) · Neoplasms, Germ Cell and Embryonal (1554) · Neuroectodermal Tumors (1553) · Neoplasms (1519) · Neoplasms by Site (1088) · Neoplasms, Glandular and Epithelial (906) · Neoplasms, Neuroepithelial (753) · Neuroendocrine Tumors (729) · Nevi and Melanomas (630) · Skin Diseases (622) · Skin and Connective Tissue Diseases (622) · Skin Neoplasms (574) · Nervous System Diseases (443) · Nervous System Neoplasms (413)
Temozolomide (202) · Bevacizumab (124) · Radiotherapy (107) · Cyclophosphamide (79) · Ipilimumab (76) · Nivolumab (69) · aldesleukin (66) · pembrolizumab (64) · Carboplatin (62) · Etoposide (46) · Irinotecan (46) · Filgrastim (42) · sargramostim (41) · Cisplatin (40) · Interleukin-2 (38)
National Cancer Institute (NCI) (205) · Memorial Sloan Kettering Cancer Center (60) · M.D. Anderson Cancer Center (36) · Duke University (35) · Dana-Farber Cancer Institute (28) · Novartis Pharmaceuticals (28) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (23) · Children's Oncology Group (21) · European Organisation for Research and Treatment of Cancer - EORTC (21) · Hoffmann-La Roche (19) · Alliance for Clinical Trials in Oncology (18) · Bristol-Myers Squibb (17) · Fred Hutchinson Cancer Center (14) · Merck Sharp & Dohme LLC (14) · Eli Lilly and Company (13)
United States (1166) · France (155) · Canada (142) · Germany (134) · Italy (125) · Spain (119) · Australia (103) · United Kingdom (102) · Switzerland (80) · Belgium (73) · Netherlands (72) · Austria (39) · Sweden (35) · Denmark (34) · Poland (32)
Steven A. Rosenberg, MD, PhD (18) · Henry S. Friedman, MD (9) · Stanislaw R. Burzynski, MD, PhD (8) · David A. Reardon, MD (7) · Steven A Rosenberg, M.D. (7) · Annick Desjardins, MD, FRCPC (6) · Brian H. Kushner, MD (6)
PMID 31401903, PMID 25667295, PMID 22555974, PMID 23633099, PMID 36648215, PMID 24983357, PMID 25098701, PMID 32747469, PMID 37934000, PMID 19451433, PMID 23861247, PMID 24408395, PMID 25113840, PMID 26169613, PMID 26446943, PMID 27580889, PMID 31406564, PMID 34331515, PMID 34376578, PMID 34464163, PMID 34754076, PMID 35504244, PMID 37540556, PMID 11705489, PMID 11772431, PMID 11835236, PMID 11857322, PMID 11874634, PMID 11904735, PMID 12039921, PMID 12525516, PMID 12528778, PMID 12649108, PMID 12749708, PMID 12826605, PMID 12829671, PMID 12947072, PMID 12957454, PMID 14577912, PMID 14581425, PMID 14586216, PMID 14670747, PMID 14673042, PMID 14767498, PMID 14769135, PMID 14769136, PMID 14769138, PMID 14769140, PMID 15010069, PMID 15073859
U10CA098543 (25), 2014 (17), U10CA180886 (15), 2016 (14), P30CA008748 (14), U01CA062475 (12), U10CA025224 (12), U10CA032102 (10), 2015 (9), 2018 (9), 2023 (9), 2019 (8), N01CM62206 (8), U01CA062399 (8), 2008 (7)